Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Baselga

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2006
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumorsC Sessa, S Cresta, T Cerny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2009
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)E M Ciruelos, J Cortés, H Cortés-Funes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancerC A Hudis, A D Seidman, J P Crown, et al.
Oncogene|February 1, 2011
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerV Serra, M Scaltriti, L Prudkin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Phase II study of semisynthetic paclitaxel in metastatic breast cancerC Hudis, L Riccio, F Holmes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancerA D Seidman, D Hochhauser, M Gollub, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisJ Cortes, V Calvo, N Ramírez-Merino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2010
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancerE-H Tan, R Ramlau, A Pluzanska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2011
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisJ Cortes, V Calvo, N Ramírez-Merino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2014
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2H S Rugo, K I Pritchard, M Gnant, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2006
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumorsC Sessa, S Cresta, T Cerny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2009
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)E M Ciruelos, J Cortés, H Cortés-Funes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancerC A Hudis, A D Seidman, J P Crown, et al.
Oncogene|February 1, 2011
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerV Serra, M Scaltriti, L Prudkin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Phase II study of semisynthetic paclitaxel in metastatic breast cancerC Hudis, L Riccio, F Holmes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancerA D Seidman, D Hochhauser, M Gollub, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisJ Cortes, V Calvo, N Ramírez-Merino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2010
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancerE-H Tan, R Ramlau, A Pluzanska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2011
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisJ Cortes, V Calvo, N Ramírez-Merino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2014
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2H S Rugo, K I Pritchard, M Gnant, et al.
Pageof 17